Structure activity relationship studies of carboxamido-biaryl ethers as opioid receptor antagonists (OpRAs). Part 2

Bioorganic and Medicinal Chemistry Letters

Volumn 17, Issue 24, 2007, Pages 6841-6846

  Takeuchi, Kumiko ^a   Holloway, William G ^a   Mitch, Charles H ^a   Quimby, Steven J ^a   McKinzie, Jamie H ^a   Suter, Todd M ^a   Statnick, Michael A ^a   Surface, Peggy L ^a   Emmerson, Paul J ^a   Thomas, Elizabeth M ^a   Siegel, Miles G ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

Carboxamido biaryl ethers; Obesity; Opioid receptor antagonists (OpRAs)

Indexed keywords

6 (2,3,4,5 TETRAHYDRO 1H BENZO[C]AZEPIN 7 YLOXY)NICOTAMIDE; 6 BICYCLOOXYNICOTINAMIDE DERIVATIVE; AMIDE; DELTA OPIATE RECEPTOR; KAPPA OPIATE RECEPTOR; LY 255582; MORPHINE; MU OPIATE RECEPTOR; NALTREXONE; NICOTINAMIDE; OPIATE ANTAGONIST; UNCLASSIFIED DRUG;

ARTICLE; BODY MASS; DRUG POTENCY; DRUG RECEPTOR BINDING; HUMAN; IN VITRO STUDY; OBESITY; PREVALENCE; RISK BENEFIT ANALYSIS; STRUCTURE ACTIVITY RELATION;

ACRYLIC RESINS; AMIDES; CARBOXYLIC ACIDS; ETHERS; MOLECULAR STRUCTURE; RECEPTORS, OPIOID; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 35848945462     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2007.10.025     Document Type: Article

References (12)

1. A brief summary of the epidemic of obesity and its health and economic impact, see. Stein C.J., and Colditz G.A. J. Clin. Endocrinol. Metab. 89 (2004) 2522 and references cited therein
2. Scheen A.J., and Ernest P.H. Diabetes Metab. 28 (2002) 437
3. Patel P.N., and Pathak R. Am. J. Health Syst. Pharm. 64 (2007) 481
4. Bray G.A., and Ryan D.H. Gastroenterology 132 (2007) 2239
5. Mitch C.H., Leander J.D., Mendelsohn L.G., Shaw W.N., Wong D.T., Cantrell B.E., Johnson B.G., Reel J.K., Snoddy J.D., Takemori A.E., and Zimmerman D.M. J. Med. Chem. 36 (1993) 2842
6. Statnick M.A., Tinsley F.C., Eastwood B.J., Suter T.M., Mitch C.H., and Heiman M.L. Am. J. Physiol. Regul. Integr. Comp. Physiol. 284 (2003) R1399
7. Takeuchi K., Holloway W.G., Mitch C.H., Quimby S.J., McKinzie J.H., Suter T.M., Statnick M.A., Surface P.L., Emmerson P.J., Thomas E.M., and Siegel M.G. Bioorg. Med. Chem. Lett. 17 (2007) 5349
8. 3H]-bremazocine binding) opioid receptors expressed in CHO cells under high sodium conditions. Under low sodium binding conditions the affinity was reduced at the receptor subtypes, consistent with findings on the prototype Lilly 4-phenylpiperidine opioid antagonist series: see. Emmerson P.J., McKinzie J.H., Surface P., Suter T.M., Mitch C.H., and Statnick M.A. Eur. J. Pharmacol. 494 (2004) 121
9. In vitro functional assay, inhibiting agonist stimulated G-protein activation (measured using GTPγS binding) in CHO membranes expressing the cloned human mu, kappa, and delta receptors. In the present study, opioid ligand binding and GTPγS functional assays were converted to a homogeneous SPA permitting the development of simpler assays with dramatically increased throughput. Optimization in the presence of sodium chloride was designed to bias these assays toward the detection of opioid antagonists. Kb values for compounds with modest binding affinities were not determined. See. Rodgers G., Hubert C., McKinzie J., Suter T., Statnick M., Emmerson P., and Stancato L. Assay Drug Dev. Technol. 1 (2003) 627 for the assay development method
10. 1H NMR, MS, and one of the following methods for purity verification: HRMS, EA or HPLC. See WO2004026305 (A1) for details of compound preparation.
11. Kucznierz R., Grams F., Leinert H., Marzenell K., Engh R.A., and von der Saal W. J. Med. Chem. 41 (1998) 4983
12. Shtacher G., Erez M., and Cohen S. J. Med. Chem. 16 (1973) 516